Market Participants Recognise Cosmo Pharmaceuticals N.V.'s (VTX:COPN) Revenues
May 02
Swiss (SMI) Pharma Industry Analysis
UpdatedMay 05, 2024
DataAggregated Company Financials
Companies7
- 7D-1.2%
- 3M-3.7%
- 1Y-15.1%
- YTDn/a
Over the last 7 days, the Pharma industry has dropped 1.2%, driven by pullbacks in Novartis and Roche Holding of 1.7% and 1.7%, respectively. Overall the industry is down 15% in 12 months. Looking forward, earnings are forecast to grow by 10% annually.
Industry Valuation and Performance
Has the Swiss Pharma Industry valuation changed over the past few years?
| Date | Market Cap | Revenue | Earnings | PE | Absolute PE | PS |
|---|---|---|---|---|---|---|
| Sun, 05 May 2024 | CHF389.1b | CHF113.1b | CHF19.9b | 39x | 19.6x | 3.4x |
| Tue, 02 Apr 2024 | CHF407.1b | CHF112.0b | CHF19.4b | 38.1x | 21x | 3.6x |
| Thu, 29 Feb 2024 | CHF386.0b | CHF110.3b | CHF19.7b | 24.4x | 19.6x | 3.5x |
| Sat, 27 Jan 2024 | CHF413.8b | CHF120.2b | CHF18.8b | 27x | 22.1x | 3.4x |
| Mon, 25 Dec 2023 | CHF394.7b | CHF119.6b | CHF18.7b | 25x | 21.1x | 3.3x |
| Wed, 22 Nov 2023 | CHF388.9b | CHF121.4b | CHF18.9b | 24.3x | 20.5x | 3.2x |
| Fri, 20 Oct 2023 | CHF390.5b | CHF121.1b | CHF18.6b | 25.6x | 21x | 3.2x |
| Sun, 17 Sep 2023 | CHF413.1b | CHF112.7b | CHF18.0b | 47x | 22.9x | 3.7x |
| Tue, 15 Aug 2023 | CHF413.2b | CHF111.6b | CHF17.9b | 49x | 23.1x | 3.7x |
| Thu, 13 Jul 2023 | CHF404.4b | CHF113.6b | CHF18.7b | 36.2x | 21.7x | 3.6x |
| Sat, 10 Jun 2023 | CHF428.7b | CHF115.5b | CHF18.9b | 37.9x | 22.7x | 3.7x |
| Mon, 08 May 2023 | CHF436.5b | CHF114.8b | CHF18.8b | 42.1x | 23.2x | 3.8x |
| Wed, 05 Apr 2023 | CHF414.6b | CHF115.4b | CHF18.9b | 42x | 21.9x | 3.6x |
| Fri, 03 Mar 2023 | CHF401.8b | CHF117.1b | CHF19.2b | 27.1x | 21x | 3.4x |
| Sun, 29 Jan 2023 | CHF445.2b | CHF118.0b | CHF34.9b | 23.6x | 12.8x | 3.8x |
| Tue, 27 Dec 2022 | CHF438.2b | CHF117.6b | CHF34.8b | 22.8x | 12.6x | 3.7x |
| Thu, 24 Nov 2022 | CHF441.2b | CHF118.1b | CHF35.0b | 23.1x | 12.6x | 3.7x |
| Sat, 22 Oct 2022 | CHF447.0b | CHF121.7b | CHF37.5b | 21.2x | 11.9x | 3.7x |
| Mon, 19 Sep 2022 | CHF449.6b | CHF119.7b | CHF36.6b | 21.5x | 12.3x | 3.8x |
| Wed, 17 Aug 2022 | CHF449.0b | CHF119.0b | CHF36.3b | 21.7x | 12.4x | 3.8x |
| Fri, 15 Jul 2022 | CHF453.9b | CHF119.9b | CHF37.9b | 27.3x | 12x | 3.8x |
| Sun, 12 Jun 2022 | CHF450.6b | CHF120.1b | CHF38.0b | 26.5x | 11.9x | 3.8x |
| Tue, 10 May 2022 | CHF476.7b | CHF120.4b | CHF38.2b | 27.7x | 12.5x | 4x |
| Thu, 07 Apr 2022 | CHF516.7b | CHF117.1b | CHF36.5b | 34.4x | 14.2x | 4.4x |
| Sat, 05 Mar 2022 | CHF456.0b | CHF116.3b | CHF36.1b | 19.2x | 12.6x | 3.9x |
| Mon, 31 Jan 2022 | CHF476.6b | CHF112.6b | CHF23.3b | 20.3x | 20.4x | 4.2x |
| Wed, 29 Dec 2021 | CHF503.4b | CHF111.9b | CHF23.2b | 21.9x | 21.7x | 4.5x |
| Fri, 26 Nov 2021 | CHF492.8b | CHF112.9b | CHF23.4b | 22.1x | 21.1x | 4.4x |
| Sun, 24 Oct 2021 | CHF492.7b | CHF111.2b | CHF22.4b | 21.7x | 22x | 4.4x |
| Tue, 21 Sep 2021 | CHF480.7b | CHF111.8b | CHF22.5b | 20.8x | 21.3x | 4.3x |
| Thu, 19 Aug 2021 | CHF541.8b | CHF111.6b | CHF22.5b | 25x | 24.1x | 4.9x |
| Thu, 03 Jun 2021 | CHF458.2b | CHF110.1b | CHF21.8b | 23.6x | 21x | 4.2x |
Price to Earnings Ratio
21x
Current Industry PE
- Investors are relatively neutral on the Swiss Pharmaceuticals industry at the moment, indicating that they anticipate long term growth rates to remain steady.
- The industry is trading close to its 3-year average PE ratio of 18.5x.
- The 3-year average PS ratio of 3.8x is higher than the industry's current PS ratio of 3.4x.
Past Earnings Growth
- The earnings for companies in the Pharmaceuticals industry have declined 3.0% per year over the last three years.
- Meanwhile revenues have remained mostly flat.
- This means that although sales have remained flat, either the cost of doing business or the level of investment back into businesses has increased, which has decreased profits.
Industry Comparison
How does Swiss Pharma compare with similar industries?
| CH Market | -0.38% | |
| Healthcare | -1.61% | |
| Pharma | -1.25% | |
| Pharma | -1.25% | |
Industry PEThere are no additional sub-industries under this industry.
Forecasted GrowthThere are no additional sub-industries under this industry.
Top Stock Gainers and Losers
Which companies have driven the market over the last 7 days?
| Company | Last Price | 7D | 1Y | Valuation | |
|---|---|---|---|---|---|
| GALD Galderma Group | CHF69.43 | 4.0% +CHF628.0m | n/a | n/a | |
| SDZ Sandoz Group | CHF31.00 | 3.3% +CHF429.7m | n/a | PE191.1x | |
| DESN Dottikon ES Holding | CHF244.00 | 4.7% +CHF151.6m | 6.3% | PE39x | |
| NWRN Newron Pharmaceuticals | CHF9.10 | 25.0% +CHF33.9m | 98.3% | PS19.2x | |
| COPN Cosmo Pharmaceuticals | CHF72.20 | 0.8% +CHF9.6m | 31.3% | PE1037x |
